RC2S+: Remediation of Social Cognitive Impairments

2016-11-30 15:45:37 | BioPortfolio



Difficulties in social interactions are a central characteristic of people with schizophrenia, and can be partly explained by impairments of social cognitive processes. According to renown researchers, three to five social cognitive processes are usually altered in schizophrenia: (1) emotional processing; (2) theory of mind (ToM); (3) attributional style; and (4 and 5) social perception and knowledge. The components of social cognition appear to be related to both symptomatology and functioning in everyday life.

New strategies of cognitive remediation have been recently developed to target these deficits and few meta analyses have assessed the extent to which social cognitive remediation programs have led to multiple improvements for schizophrenia patients. Overall, it seems that such therapies showed encouraging results in both patient interest and motivation, and social cognitive processes.

The RC2S therapy is the first individualized and partly computerized program through which patients practice social interactions and develop social cognitive abilities with simulation techniques in a realistic environment.



This is a randomized controlled trial to establish the validity of the RC2S+ program in schizophrenia.

The project's main objective is to assess the impact of RC2S+ on social cognitive impairments in schizophrenia compared with a cognitive remediation program (control therapy) focusing on neurocognition, equivalent in terms of number, duration and rhythm of sessions.

The study has four other objectives:

1. To assess the influence of the RC2S+ therapy versus control therapy on neurocognitive processes

2. To assess the impact of the RC2S+ therapy versus control therapy on social functioning

3. To assess the impact of the RC2S+ therapy versus control therapy on both positive and negative symptoms

4. To study the maintenance of benefits 3 months forward


To treat social cognitive impairments in people with schizophrenia.

Study Design

Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment




RC2S+, active comparator


Not yet recruiting


Hôpital le Vinatier

Results (where available)

View Results


Published on BioPortfolio: 2016-11-30T15:45:37-0500

Clinical Trials [1231 Associated Clinical Trials listed on BioPortfolio]

Olanzapine Versus Active Comparator in the Treatment of Depression in Patients With Schizophrenia

This is a research study comparing the safety and efficacy of two active study medications

Study of the Effect of Single Doses of MK2637 and Dextromethorphan on Cerebral Cortex Excitability

This study will assess transcranial magnetic stimulation (TMS) as a biomarker and characterize TMS readouts of the activity of MK2637 and dextromethorphan. Resting quantitative electroence...

A Study to Test the Safety and Efficacy of MK8998 in Acutely Psychotic Patients With Schizophrenia

A study to evaluate the safety and efficacy of treatment with MK8998 as compared to placebo and olanzapine for acutely psychotic patients with schizophrenia.

MK0557 for the Treatment of Cognitive Impairment in Patients With Schizophrenia.

The purpose of this study is to determine the safety and effectiveness of an investigational drug for the treatment of cognitive impairment in patients with schizophrenia.

First Time in Human Study With GSK1018921

GSK1018921 is a new drug under development for the treatment of schizophrenia. GSK1018921 differs from other available drugs in its mode of action and it is assumed that it may have an eff...

PubMed Articles [5626 Associated PubMed Articles listed on BioPortfolio]

Liquid Formulation of AbobotulinumtoxinA Exhibits a Favorable Efficacy and Safety Profile in Moderate to Severe Glabellar Lines: A Randomized, Double-Blind, Placebo- and Active Comparator-Controlled Trial.

Barbara Fish and a Short History of the Neurodevelopmental Hypothesis of Schizophrenia.

The neurodevelopmental hypothesis of schizophrenia has become a paradigm broadly accepted in today's research in schizophrenia and its spectrum. This article traces the historical development of the n...

Randomized, Double-Blind, Placebo- and Active Comparator-Controlled Crossover Study Evaluating the Abuse Potential of the Antiepileptic Drug Lacosamide in Healthy Recreational Drug Users.

This phase 1, randomized, double-blind, placebo- and active comparator-controlled crossover study assessed the abuse potential of the antiepileptic drug, lacosamide.

«Verschroben»-phenomenon in schizophrenia and schizophrenia spectrum disorders: aspects of systematics.

Psychopathological analysis and typological differentiation of «verschroben»-phenomenon as the full-blown syndrome of defect in schizophrenia and schizophrenia spectrum disorders.

Update on the 22q11.2 deletion syndrome and its relevance to schizophrenia.

Schizophrenia occurs in ∼25% of individuals with 22q11.2 deletion syndrome (22q11.2DS), the strongest known molecular genetic risk factor for schizophrenia. This review highlights recent literature ...

Medical and Biotech [MESH] Definitions

A chronic form of schizophrenia characterized primarily by the presence of persecutory or grandiose delusions, often associated with hallucination.

A type of schizophrenia characterized by abnormality of motor behavior which may involve particular forms of stupor, rigidity, excitement or inappropriate posture.

An obsolete concept, historically used for childhood mental disorders thought to be a form of schizophrenia.

A benzisoxazole derivative and active metabolite of RISPERIDONE that functions as a DOPAMINE D2 RECEPTOR ANTAGONIST and SEROTONIN 5-HT2 RECEPTOR ANTAGONIST. It is an ANTIPSYCHOTIC AGENT used in the treatment of SCHIZOPHRENIA.

A type of schizophrenia characterized by frequent incoherence; marked loosening of associations, or grossly disorganized behavior and flat or grossly inappropriate affect that does not meet the criteria for the catatonic type; associated features include extreme social withdrawal, grimacing, mannerisms, mirror gazing, inappropriate giggling, and other odd behavior. (Dorland, 27th ed)

More From BioPortfolio on "RC2S+: Remediation of Social Cognitive Impairments"

Quick Search

Searches Linking to this Trial